Pregabalin Capsule
Product Images NDC 71205-338

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-338-30 (Pregabalin 100mg 1000)

Label for Pregabalin 100 mg capsules, quantity 30, packaged by Proficient Rx LP. The label states the active ingredient as 100 mg Pregabalin per capsule, identifies it as a Schedule V controlled substance (C-V), and includes storage instructions. The manufacturer is Laurus Labs Limited, India. The label features the ProficientRx logo and notes the product is prescription only.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of Pregabalin. The diagram depicts the molecular structure showing carbon, hydrogen, amino (NH2), and carboxyl (CO2H) groups arranged to represent Pregabalin's chemical composition.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula illustrating the calculation of creatinine clearance (CLCr), factoring age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier for female patients (0.85).*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A chart depicting the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Four lines represent Pregabalin dosed at 200 mg, 100 mg, and 25 mg three times a day, and a placebo group, showing different levels of patient pain improvement.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph depicting the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares Pregabalin 100 mg taken three times a day with placebo, showing distinct curves for each treatment group over varying levels of pain improvement.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 300 mg, 150 mg, 75 mg (each taken twice a day), and placebo, with higher doses generally showing greater patient improvement in pain reduction.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing the percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient pain improvement trends over varying percentages of pain relief.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing percent improvement in pain from baseline (x-axis) versus percent of patients involved (y-axis). It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The data demonstrate patient response trends over increasing levels of pain improvement.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar chart depicting responder rates (%) in two clinical studies labeled Study E1 and Study E3. The x-axis shows treatment groups including placebo and various dosages of pregabalin (50 mg, 80 mg, 300 mg, 600 mg, and 600 mg twice daily). The y-axis shows responder rates ranging from 0% to 60%. The chart illustrates increasing responder rates with higher doses of pregabalin compared to placebo.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg per day for Pregabalin. The graph compares data from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, showing seizure reduction increasing with higher doses up to around 600 mg/day. Statistical significance values (p-values) are indicated for various dose points, demonstrating significant seizure reduction compared to placebo.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

Line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 600 mg, 450 mg, and 300 mg daily doses compared to placebo. The graph compares efficacy across different dosing levels.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve chart comparing estimated percentages of subjects without LTR over days for Pregabalin and placebo groups. The x-axis represents days, and the y-axis shows the percentage of subjects without LTR, with Pregabalin consistently showing higher survival percentages than placebo across the timeline up to 180 days.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line chart comparing the percentage of subjects improved over time from baseline to week 12, showing two lines for Pregabalin and Placebo. The x-axis represents the percent improved from baseline, while the y-axis shows the percent of subjects improved. The Pregabalin group has a consistently higher improvement percentage than the Placebo group across the measured range.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 16 BOCF for Pregabalin versus Placebo. The x-axis shows percent improvement, and the y-axis shows the percent of subjects improved. Two lines are plotted, one solid for Pregabalin and one dashed for Placebo, showing the difference in improvement rates between the two groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.